Targeted treatment for sonic hedgehog-dependent medulloblastoma

Neuro-Oncology

Volumn 16, Issue 8, 2014, Pages 1037-1047

  Kieran, Mark W ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Expression profiling; Hedgehog; Medulloblastoma; Targeted therapy

Indexed keywords

G PROTEIN COUPLED RECEPTOR; SMO PROTEIN, HUMAN; SONIC HEDGEHOG PROTEIN;

CEREBELLAR NEOPLASMS; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MEDULLOBLASTOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CEREBELLAR NEOPLASMS; GENE EXPRESSION PROFILING; HEDGEHOG PROTEINS; HUMANS; MEDULLOBLASTOMA; MOLECULAR TARGETED THERAPY; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84904366574     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou109     Document Type: Review

References (115)

1. Rossi A, Caracciolo V, Russo G, et al. Medulloblastoma: From molecular pathology to therapy. Clin Cancer Res. 2008;14(4): 971-976 (Pubitemid 351302541)
2. Samkari A, Hwang E, Packer RJ. Medulloblastoma/primitive neuroectodermal tumor and germ cell tumors: The uncommon but potentially curable primary brain tumors. Hematol Oncol Clin North Am. 2012;26(4):881-895
3. Garrè ML, Cama A, Bagnasco F, et al. Medulloblastoma variants: Age-dependent occurrence and relation to Gorlin syndrome-A new clinical perspective. Clin Cancer Res. 2009;15(7):2463-2471
4. Hahn H, Wicking C, Zaphiropoulos PG, et al. Mutations of the human homolog of drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841-851 (Pubitemid 26192135)
5. Northcott PA, Shih DJ, Remke M, et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2012;123(4):615-626
6. Schwalbe EC, Lindsey JC, Straughton D, et al. Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res. 2011; 17(7):1883-1894
7. Amakye D, Robinson D, Rose K, et al. The predictive value of a 5-gene signature as a patient pre-selection tool in medulloblastoma for hedgehog pathway inhibitor therapy [abstract 4818]. Cancer Res. 2012;72:(8 suppl 1
8. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: An international meta-Analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathol. 2012;123(4): 473-484
9. Teglund S, Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta. 2010;1805(2): 181-208
10. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996;14(1):78-81 (Pubitemid 26301550)
11. Lorusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8): 2502-2511
12. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009; 361(12):1173-1178
13. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179
14. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180-2188
15. Gajjar AJ, Gururangan S, Qaddoumi IA, et al. A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB):a Pediatric Brain Tumor Consortium study (PBTC 25B) [abstract 2035]. J Clin Oncol. 2013; 31:(suppl
16. Gajjar A, Stewart CF, Ellison DW, et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: A Pediatric Brain Tumor Consortium study. Clin Cancer Res. 2013;19(22): 6305-6312
17. Jimeno A, Weiss GJ, Miller WH Jr, et al. Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013;19(10):2766-2774
18. Rodon J, Tawbi HA, Thomas AL, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014;20(7):1900-1909
19. Kieran M, Geoerger B, Casanova M, et al. A phase 1/2 safety and preliminary efficacy study of sonidegib (LDE225), a hedgehog pathway inhibitor, in pediatric and adult patients with relapsed or refractory medulloblastoma and other solid tumors [abstract NO-068]. Neuro Oncol. 2013;15:(suppl 3
20. Erivedge (vismodegib) [package insert]. South San Francisco, CA: Genentech USA, Inc; 2012
21. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov. Accessed February 18, 2014
22. Packer RJ, Cogen P, Vezina G, et al. Medulloblastoma: Clinical and biologic aspects. Neuro Oncol. 1999;1(3):232-250
23. von Bueren AO, von Hoff K, Pietsch T, et al. Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro Oncol. 2011;13(6): 669-679
24. Mulhern RK, Palmer SL, Merchant TE, et al. Neurocognitive consequences of risk-Adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005;23(24):5511-5519
25. Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: Therapy at a crossroads. Arch Neurol. 2008; 65(11):1419-1424
26. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers V 2.2013. Available at http://www.nccn.org/professionals/physician-gls/pdf/cns.pdf. Accessed February 18, 2014
27. Bartlett F, Kortmann R, Saran F. Medulloblastoma. Clin Oncol (R Coll Radiol). 2013;25(1):36-45
28. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109 (Pubitemid 47103521)
29. Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29(11):1424-1430
30. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011; 29(11):1408-1414
31. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008;3(8): E3088
32. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24(12):1924-1931 (Pubitemid 46638992)
33. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol. 2012; 123(4):465-472
34. McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol. 2003;53:1-114 (Pubitemid 137639458)
35. Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 2003;3(12): 903-911 (Pubitemid 37500175)
36. Kimura H, Ng JM, Curran T. Transient inhibition of the hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell. 2008;13(3):249-260 (Pubitemid 351324879)
37. Varjosalo M, Taipale J. Hedgehog: Functions and mechanisms. Genes Dev. 2008;22(18):2454-2472
38. Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by sonic hedgehog. Neuron. 1999; 22(1):103-114 (Pubitemid 29070097)
39. Wallace VA. Purkinje-cell-derived sonic hedgehog regulates granule neuron precursor cell proliferation in the developing mouse cerebellum. Curr Biol. 1999;9(8):445-448 (Pubitemid 29205791)
40. Schuller U, Heine VM, Mao J, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell. 2008;14(2):123-134
41. Han YG, Kim HJ, Dlugosz AA, et al. Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med. 2009; 15(9):1062-1065
42. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Annu Rev Pathol. 2008;3:341-365 (Pubitemid 351488285)
43. Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331(6016): 435-439
44. Slade I, Murray A, Hanks S, et al. Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Fam Cancer. 2011;10(2): 337-342
45. Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer. 2000;27(1):44-51
46. Brugieres L, Remenieras A, Pierron G, et al. High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol. 2012;30(17):2087-2093
47. Northcott PA, Hielscher T, Dubuc A, et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol. 2011;122(2):231-240
48. Buczkowicz P, Ma J, Hawkins C. GLI2 is a potential therapeutic target in pediatric medulloblastoma. J Neuropathol Exp Neurol. 2011;70(6):430-437
49. Kool M, Jones DT, Jager N, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014;25(3):393-405
50. Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012; 488(7409):49-56
51. Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013;31(23):2927-2935
52. Ramaswamy V, Remke M, Bouffet E, et al. Recurrence patterns across medulloblastoma subgroups: An integrated clinical and molecular analysis. Lancet Oncol. 2013;14(12):1200-1207
53. Sengupta R, Dubuc A, Ward S, et al. CXCR4 activation Defines a new subgroup of sonic hedgehog-driven medulloblastoma. Cancer Res. 2012;72(1):122-132
54. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/2)p53(2/2) mice. Cancer Cell. 2004; 6(3):229-240 (Pubitemid 39222036)
55. Sasai K, Romer JT, Lee Y, et al. Shh pathway activity is down-regulated in cultured medulloblastoma cells: Implications for preclinical studies. Cancer Res. 2006;66(8):4215-4222
56. Lee MJ, Hatton BA, Villavicencio EH, et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci USA. 2012;109(20): 7859-7864
57. Rohner A, Spilker ME, Lam JL, et al. Effective targeting of hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective smoothened antagonist that penetrates the blood-brain barrier. Mol Cancer Ther. 2012;11(1):57-65
58. Bender MH, Hipskind PA, Capen AR, et al. Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling [abstract 2819]. Cancer Res. 2011;71(8
59. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3 K pathway in medulloblastoma. Sci Transl Med. 2010;2(51):51ra70
60. Kenney AM, Cole MD, Rowitch DH. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in Developing cerebellar granule neuron precursors. Development. 2003;130(1):15-28 (Pubitemid 36113940)
61. Northcott PA, Fernandez-L A, Hagan JP, et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehogtreated cerebellar neural precursors. Cancer Res. 2009;69(8): 3249-3255
62. Colvin Wanshura LE, Galvin KE, Ye H, et al. Sequential activation of Snail1 and N-myc modulates sonic hedgehog-induced transformation of neural cells. Cancer Res. 2011;71(15):5336-5345
63. Briggs KJ, Corcoran-Schwartz IM, Zhang W, et al. Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Genes Dev. 2008;22(6):770-785 (Pubitemid 351439108)
64. Ahlfeld J, Favaro R, Pagella P, et al. Sox2 requirement in sonic hedgehog-Associated medulloblastoma. Cancer Res. 2013;73(12): 3796-3807
65. Swartling FJ, Savov V, Persson AI, et al. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 2012;21(5):601-613
66. Garcia I, Crowther AJ, Gershon TR. ASPM, a target of sonic hedgehog, is a key element in cerebellar development and medulloblastoma pathogenesis [abstract MB-51]. Neuro Oncol. 2012;14:(suppl 1
67. Bar EE, Chaudhry A, Eberhard CG. Hedgehog signaling promotes medulloblastoma survival via Bcl2 [abstract 4080]. Proc Amer Assoc Cancer Res. 2006;7
68. Fults D, McCall T, Pedone C. Apoptosis suppression by somatic cell transfer of bcl-2 promotes sonic hedgehog-dependent medulloblastoma formation in mice [abstract 3885]. Presented at: 98th Annual Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, CA
69. Wang X, Venugopal C, Manoranjan B, et al. Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene. 2012;31(2):187-199
70. Subkhankulova T, Zhang X, Leung C, et al. Bmi1 directly represses p21Waf1/Cip1 in Shh-induced proliferation of cerebellar granule cell progenitors. Mol Cell Neurosci. 2010;45(2):151-162
71. Manoranjan B, Hallett R, Venugopal C, et al. Bmi1 regulation of sonic hedgehog signaling through the E3 ubiquitin ligase Cullin3 in medulloblastoma stem cells [abstract MB-49]. Neuro Oncol. 2012; 14:(suppl 1
72. Yang L, Jackson E, Woerner BM, et al. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007;67(2):651-658 (Pubitemid 46192204)
73. Bhatia B, Hsieh M, Kenney AM, et al. Mitogenic sonic hedgehog signaling drives E2F1-dependent lipogenesis in progenitor cells and medulloblastoma. Oncogene. 2011;30(4):410-422
74. Bhatia B, Potts CR, Guldal C, et al. Hedgehog-mediated regulation of PPARg controls metabolic patterns in neural precursors and shh-driven medulloblastoma. Acta Neuropathol. 2012;123(4): 587-600
75. Malhotra A, Potts C, Fernandez-Lopez A, et al. Signaling network-based analyses of sonic hedgehog pathway components: Predictions and possibilities [abstract CB-56]. Neuro Oncol. 2012;14:(suppl 6
76. Rao G, Pedone CA, Del Valle L, et al. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene. 2004;23(36):6156-6162 (Pubitemid 39178868)
77. Guldal C, Potts C, Rotenberry R, et al. HIF1 downstream of sonic hedgehog mitogenic and oncogenic signaling and brain Development and medulloblastoma [abstract PL-12]. Neuro Oncol. 2012;14:(suppl 6
78. Baryawno N, Sveinbjornsson B, Kogner P, et al. Medulloblastoma: A disease with disorganized developmental signaling cascades. Cell Cycle. 2010;9(13):2548-2554
79. Dakubo GD, Mazerolle CJ, Wallace VA. Expression of Notch and Wnt pathway components and activation of Notch signaling in medulloblastomas from heterozygous patched mice. J Neurooncol. 2006;79(3):221-227 (Pubitemid 44363724)
80. Snuderl M, Batista A, Kirkpatrick ND, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell. 2013;152(5):1065-1076
81. Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004; 64(21):7794-7800 (Pubitemid 39446912)
82. Parathath SR, Mainwaring LA, Fernandez-L A, et al. Insulin receptor substrate 1 is an effector of sonic hedgehog mitogenic signaling in cerebellar neural precursors. Development. 2008;135(19): 3291-3300
83. Bhatia B, Nahle Z, Kenney AM. Double trouble: When sonic hedgehog signaling meets TSC inactivation. Cell Cycle. 2010;9(3): 456-459
84. Mainwaring LA, Kenney AM. Divergent functions for eIF4E and S6 kinase by sonic hedgehog mitogenic signaling in the developing cerebellum. Oncogene. 2011;30(15):1784-1797
85. Browd SR, Kenney AM, Gottfried ON, et al. N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma. Cancer Res. 2006;66(5): 2666-2672
86. Fernandez-L A, Squatrito M, Northcott P, et al. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene. 2012;31(15):1923-1937
87. Cohen JR, Resnick DZ, Niewiadomski P, et al. Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures. BMC Cancer. 2010;10:676-683
88. Nicot A, Lelievre V, Tam J, et al. Pituitary adenylate cyclaseactivating polypeptide and sonic hedgehog interact to control cerebellar granule precursor cell proliferation. J Neurosci. 2002; 22(21):9244-9254 (Pubitemid 35356168)
89. Kadel E, DuPree K, Lee S, et al. Development of a clinical hedgehog antagonist qRT-PCR pharmacodynamic assay for Gli1 in hair follicle samples [abstract 3656]. Presented at: 99th Annual Meeting of the American Association for Cancer Research; April 12-16, 2008; San Diego, CA
90. Rose K, Robinson D, Sharp T, et al. Gene expression analysis in human hair bulbs as a potential pharmacodynamic readout in the LDE225 clinical program [abstract 3092]. J Clin Oncol. 2010; 28:(15s
91. Amakye D, Robinson D, Rose K, et al. Development of a five-gene Hedgehog signature as a patient preselection tool for Hedgehog pathway-Targeted therapy in medulloblastoma [abstract 0125]. Neuro Oncol. 2013;15:(suppl 1
92. Kieran MW, Hargrave D, Wen PY, et al. A phase 3, multicenter, open-label, randomized, controlled study of the efficacy and safety of oral sonidegib (LDE225) versus temozolomide in patients with hedgehog pathway-Activated relapsed medulloblastoma [abstract NO-069]. Neuro Oncol. 2013;15:(suppl 3
93. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326(5952):572-574
94. Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011; 71(2):435-444
95. Cao X, Zhu H, Bigner D, et al. Gain-of-function tGLI1 transcription factor augments anchorage-independent growth of medulloblastoma cells and confers their resistance to SMO inhibitors [abstract 0039]. Neuro Oncol. 2011;13:(suppl 1
96. He J, Sheng T, Stelter AA, et al. Suppressing Wnt signaling by the hedgehog pathway through sFRP-1. J Biol Chem. 2006;281(47): 35598-35602 (Pubitemid 46041289)
97. van Den Brink GR, Bleuming SA, Hardwick JC, et al. Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. Nat Genet. 2004;36(3):277-282 (Pubitemid 38282753)
98. Akiyoshi T, Nakamura M, Koga K, et al. Gli1, downregulated in colorectal cancers, inhibits proliferation of colon cancer cells involving Wnt signalling activation. Gut. 2006;55(7):991-999 (Pubitemid 43962612)
99. Tao H, Jin Q, Koo DI, et al. Small molecule antagonists in Distinct binding modes inhibit drug-resistant mutant of smoothened. Chem Biol. 2011;18(4):432-437
100. Wang J, Mook R, Lyerly HK, et al. Candidate hedgehog/smoothened inhibitors for pediatric medulloblastoma [abstract 0080]. Neuro Oncol. 2011;13:(suppl 1
101. Lauth M, Bergstrom A, Shimokawa T, et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA. 2007; 104(20):8455-8460 (Pubitemid 47175509)
102. Hyman JM, Firestone AJ, Heine VM, et al. Small-molecule inhibitors reveal multiple strategies for hedgehog pathway blockade. Proc Natl Acad Sci USA. 2009;106(33):14132-14137
103. Ohashi T, Oguro Y, Tanaka T, et al. Discovery of pyrrolo[3,2-c]quinoline- 4-one derivatives as novel hedgehog signaling inhibitors. Bioorg Med Chem. 2012;20(18):5496-5506
104. Wickstrom M, Dyberg C, Shimokawa T, et al. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer. 2013; 132(7):1516-1524
105. Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 2011;121(1): 148-160
106. Kim J, Lee JJ, Kim J, et al. Arsenic antagonizes the hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA. 2010;107(30):13432-13437
107. Pambid MR, Berns R, Hu K, et al. Overcoming resistance to sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase for the management of medulloblastoma [abstract 0013]. Neuro Oncol. 2013;15:(suppl 1
108. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388-399
109. Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23(1):23-34
110. Aftab B, Kim J, Yang JY, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to vismodegib [abstract 5644]. Cancer Res. 2013;73:(8 suppl 1
111. Wang Y, Davidow L, Arvanites AC, et al. Glucocorticoid compounds modify smoothened localization and hedgehog pathway activity. Chem Biol. 2012;19(8):972-982
112. Drenkhahn SK, Jackson GA, Slusarz A, et al. Inhibition of Hedgehog/Gli signaling by botanicals: A review of compounds with potential hedgehog pathway inhibitory activities. Curr Cancer Drug Targets. 2013;13(5):580-595
113. Murphy BL, Obad S, Bihannic L, et al. Silencing of the miR-17-92 cluster family inhibits medulloblastoma progression. Cancer Res. 2013;73(23):7068-7078
114. Corcoran RB, Bachar Raveh T, Barakat MT, et al. Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous mice. Cancer Res. 2008;68(21): 8788-8795
115. Lelievre V, Seksenyan A, Nobuta H, et al. Disruption of the PACAP gene promotes medulloblastoma in ptc1 mutant mice. Dev Biol. 2008;313(1):359-370 (Pubitemid 350298324)